

CURRICULUM VITAE
Mark H. Townsend, M.D., S.M.
Professor, Department of Psychiatry
Louisiana State University Health Sciences Center New Orleans

Date December 30, 2015

Contact Information

Business Address: Department of Psychiatry
Louisiana State University Health Sciences Center
1542 Tulane Avenue
New Orleans, LA 70112

Business Phone Number: 504.568.6009
Fax: 504.568.6006
Email: mtowns@lsuhsc.edu

Education

1988 M.D., Tulane University School of Medicine
1983 S.M., Human Biology, University of Chicago
1981 A.B., Biology (with Honors), University of Chicago

Graduate Education and Training

1991-1992 Chief Resident, Psychiatry, Louisiana State University Health Sciences
Center New Orleans
1989-1992 Residency, Psychiatry, Louisiana State University Health Sciences Center
New Orleans
1988-1989 Internship, Louisiana State University Health Sciences Center New
Orleans

Certifications

1995-2025 Diplomat, American Board of Psychiatry and Neurology

Medical Licensures

Active California
Active Louisiana

Employment History

Academic Appointments

1992-1997	Assistant Professor of Psychiatry, Louisiana State University Health Sciences Center New Orleans
1997-2006	Associate Professor of Psychiatry (tenured), Louisiana State University Health Sciences Center New Orleans
2006-present	Professor of Psychiatry, Louisiana State University Health Sciences Center New Orleans

Other Employment

2008-present	Clinical Professor of Psychiatry, Tulane University School of Medicine
2008-present	Teaching Scholar, Academy for the Advancement of Educational Scholarship, Louisiana State University Health Sciences Center New Orleans

Professional Society Memberships

1988	Member-in-Training, American Psychiatric Association
1988	Member, Louisiana Psychiatric Medical Association
1992	General Member, American Psychiatric Association
1992	Member, Gay and Lesbian Medical Association
1994	Member, American Medical Association
1995	Member, Anxiety and Depression Association of America
2000	Member, Association of Directors of Medical Student Education in Psychiatry
2005,	Member, International Society for Bipolar Disorders
2006	Distinguished Fellow, American Psychiatric Association
2014	Member, Association for Academic Psychiatry
2015	Member, American Society for Clinical Psychopharmacology

Honors and Awards

1993	NIH/NIMH New Investigator's Award
1998	Faculty Member of the Year, LSUHSC New Orleans, Department of Psychiatry
2009	Best Paper, Annual Meeting of Directors of Medical Student Education in Psychiatry
2009	Irma Bland Award for Teaching in Graduate Medical Education, American Psychiatric Association
2010	James Paulsen Award, Association of Gay and Lesbian Psychiatrists
2011	George C Dunn Professor of Psychiatry, Louisiana State University Health Sciences Center New Orleans

2013 Outstanding Presentation Award for Medical Education Scholarship Research and Evaluation, Southern Group on Educational Affairs (Levine R.E., presenter and lead author)

Clinical Activities

1992-present Medical Staff Member, Medical Center of Louisiana at New Orleans (MCLNO)

1992-present Medical Staff Member, Touro Infirmary, New Orleans, Louisiana

1992-present Outpatient Psychiatrist, LSU Healthcare Network
--Currently treat more than 1000 adults, primarily with anxiety and mood disorders

1992-1996 Staff Psychiatrist, Dual Diagnosis Unit, MCLNO

1992-1994 Staff Psychiatrist, Health Care for the Homeless Clinic, New Orleans Health Department

1996-2005 General Psychiatry Unit Director, MCLNO

1998-present Director, Behavioral Research Clinic, Department of Psychiatry, LSUHSC New Orleans
--Directs adult inpatient and outpatient pharmaceutical clinical trials for LSUHSC Psychiatry

1999-2005 Clinical Director, Partial Hospitalization Program, Medical Center of Louisiana at New Orleans
--Directed multi-professional treatment and medical education at 150-patient/year PHP associated with academic medical center

2005-2009 Medical Director for Psychiatry, Odyssey House of Louisiana
--Directed psychiatric treatment and medical education at 100-bed residential treatment program for adults with addictive disorders

2005-2007 Medical Director, Assertive Community Treatment Program, Louisiana Office of Behavioral Health
--Directed multi-professional outreach team to 125 individuals with severe psychiatric illness living in post-Katrina metropolitan New Orleans

2007-2015 Hospital Center Director for Psychiatry, Interim LSU Hospital (ILH)

Institutional Service

1997-1998	Member, Compliance Committee LSU Healthcare Network
1998-present	Member/Alternate, LSUHSC Institutional Review Board
1999-2005	Member, Mental Health Subcommittee, Pharmacy and Therapeutics Committee, Medical Center of Louisiana at New Orleans
1999-present	Director of Medical Student Education in Psychiatry, LSU School of Medicine New Orleans
1999-present	Member, Graduate Education Committee, LSUHSC Department of Psychiatry
1999-present	Member, Medical Student Promotions Committee, LSU School of Medicine New Orleans
2002-present	Member, Curriculum Oversight Committee, LSU School of Medicine New Orleans
2005-present	Member, Pharmacy and Therapeutics Committee, Interim LSU Public Hospital
2006-present	Vice Chair for General Adult Psychiatry, LSUHSC Department of Psychiatry
2007-2015	Member, Credentials Committee, Interim LSU Public Hospital
2007-2015	Member, Medical Executive Committee, Interim LSU Public Hospital
2008-2010	Member, Academic Hospital Design Steering Committee
2008-2012	Member, Advisory Board, Tulane-LSU General Clinical Research Center
2012-2015	Member, Bylaws Committee, Interim LSU Public Hospital
2012-present	Chair, Medical Student Promotions Committee, LSU School of Medicine New Orleans
2012-present	Faculty Advisor, "Rampart House" LSU School of Medicine, New Orleans
2015-present	Vice Chair for Education

Local Service

2015-present	President-elect, Louisiana Psychiatric Medical Association
2012-present	Behavioral Health Interagency Council, City of New Orleans Health Department
2006-present	Chair, Membership Committee, Louisiana Psychiatric Medical Association
1994-present	Member, Executive Committee, Louisiana Psychiatric Medical Association

National Service

1997-2002	Editor-in-Chief, <i>Journal of the Gay and Lesbian Medical Association</i> , Boston: Kluwer Academic Press
2011-present	Representative, Assembly of the American Psychiatric Association
2011	Reviewer, <i>MedEdPORTAL</i>

- 2010-2013 Member, Membership Committee, American Psychiatric Association
 2009-2010 Member, Assembly Executive Committee, American Psychiatric Association
 2009-2010 Chair, Assembly Committee of Representatives of Minority/Under-represented Caucuses, American Psychiatric Association
 2009 Ad Hoc Reviewer, *Schizophrenia Research*
 2008-2013 Member, Editorial Board, *Journal of Gay and Lesbian Mental Health*, Philadelphia: Taylor & Francis.
 2008 Ad Hoc Reviewer, *Bipolar Disorders*
 2007 Ad Hoc Reviewer, *Academic Psychiatry*
 2006-2010 Representative, Assembly of the American Psychiatric Association,
 2005 Ad Hoc Reviewer, *Teaching and Learning in Medicine*
 2005 Ad Hoc Reviewer, *Psychiatric Services*
 2004-2009 Member, Committee on Medical Student Education, American Psychiatric Association
 2004-2009 Member, Committee on Medical Student Education, American Psychiatric Association
 2002 Ad Hoc Reviewer, *Bipolar Disorders*
 2002 Ad Hoc Reviewer, *Comprehensive Psychiatry*
 2000 Ad Hoc Reviewer, *Schizophrenia Research*
 1993-1999 Member, Committee on Gay and Lesbian Issues, American Psychiatric Association

Teaching Service

First- through Fourth-year medical students

2012-present Faculty, Rampart House

First-year medical students

1992-present Small group leader, Science and Practice of Medicine 100, LSU School of Medicine New Orleans, 10 1st year students, 40 hours/year

Second-year medical students

1992-present Lecturer, Psychiatry and Medicine 200, LSU School of Medicine New Orleans, 180 2nd year students, 6 hours/year

Third-year medical students

1998-present Clerkship director, Psychiatry 300, LSU School of Medicine New Orleans 180 3rd year students, hours/year instruction

2006-present Site director, Psychiatry 300, LSU School of Medicine New Orleans, 18
3rd year students on unit attended by me, 100 hours/year

Fourth-year medical students

1998- present Course director, Psychiatry 400 Acting Internship in Psychiatry
10 4th year students, 100 hours/year

Occupational Therapy students

2006-present Lecturer, OCCT 6624 Medical Conditions, LSUHSC New Orleans
Department of Occupational Therapy, 55 students, 4 hours/year

PGY-I psychiatry residents:

1994- present Lecturer, Introduction to Psychopathology and Psychopharmacology
1992-present Supervision, Inpatient Psychiatry (LSU and Tulane residents)

PGY-III residents

2004-present Course director, Psychopharmacology Seminars
2004-present Supervision, Outpatient Psychiatry
2006-present Course director, Advanced Psychopharmacology

PGY-IV residents

1992-present Supervision, Inpatient Psychiatry Acting Attending

Visiting professorships

1996-2003 Lecturer, Liberal Studies 1000, Millsaps College, Jackson, Mississippi

Publications

Peer-reviewed journal articles

1. Uehara A, Minamino N, Townsend MH, Arimura A. Corticotropin-releasing factor in rat gastric antrum. *Proceedings of the Society for Experimental Biology and Medicine* 1986, 106-113.
2. Townsend M.H., Wallick M.M., Cambre K.M. Support services for homosexual students at U.S. medical schools. *Academic Medicine*, 1991, 66, 361-36

3. Wallick M.W., Cambre K.M., and Townsend M.H. How the topic of homosexuality is taught at U.S. medical schools. *Academic Medicine*, 1992, 67, 601-603.
4. Wallick M.W., Cambre K.M., and Townsend M.H. Freshman students' attitudes toward homosexuality. *Academic Medicine*, 1993, 68, 357-8.
5. Mancuso D.M., Townsend M.H., Mercante D.E. Long-term follow-up of generalized anxiety disorder. *Comprehensive Psychiatry*, 1993, 34, 441-446.
6. Townsend M.H., Stock M.R., Bland I.J. The relation between panic disorder onset and homelessness in a clinic population. *Journal of Nervous and Mental Disease*, 1995, 183, 140-141.
7. Townsend M.H., Stock M.R., Morse E.V., Simon P.M. HIV, TB, and mental illness in a health clinic for the homeless. *Journal of the Louisiana State Medical Society*, 1996, 148, 267-270.
8. Barbee J.G., Kuczmierczyk A.R., Bologna N.B., Townsend M.H. Serum cholesterol levels inpatients with generalized anxiety disorder (GAD) and with GAD and comorbid major depression. *Canadian Journal of Psychiatry*, 1996, 41, 465-468.
9. Townsend, M.H., Bologna, N.B., Barbee, J.G. Heart Rate and Blood Pressure in Panic Disorder, Major Depression, and Comorbid Panic Disorder and Major Depression. *Psychiatry Research*, 1998, 79, 187-180.
10. Townsend, M.H., Weissbecker, K.A., Barbee, J.D., Peña, J.M., Snider, L.M., Tynes, L.L., Tynes, S.F., Boudoin, C., Green-Leibovitz, M.I., Winstead, D.K. Compulsive Behavior in Generalized Anxiety Disorder and Obsessive-Compulsive Disorder. *Journal of Nervous and Mental Disease*, 1999, 187, 697-699.
11. Penn, D.L., Combs, D., Ritchie, M., Francis, J., Cassisi, J., Morris, S., Townsend, M.H. Emotion recognition in schizophrenia: Further investigation of specific versus generalized performance deficit models. *Journal of Abnormal Psychology*, 2000, 109, 3, 512-516.
12. Townsend, M.H., Cambre, K.M., Barbee, J.G. Treatment of borderline personality disorder with mood instability with divalproex sodium: Series of 10 cases. *Journal of Clinical Psychopharmacology*, 2001, 21, 249-251.
13. Townsend, M.H., Bologna, N.B., Barbee, J.G. Heart Rate and Blood Pressure in Panic Disorder, Major Depression, and Comorbid Panic Disorder and Major Depression. *Psychiatry Research*, 1998, 79, 187-180.
14. Townsend, M.H., Weissbecker, K.A., Barbee, J.D., Peña, J.M., Snider, L.M., Tynes, L.L., Tynes, S.F., Boudoin, C., Green-Leibovitz, M.I., Winstead, D.K. Compulsive Behavior in Generalized Anxiety Disorder and Obsessive-Compulsive Disorder. *Journal of Nervous and Mental Disease*, 1999, 187, 697-699.
15. Penn, D.L., Combs, D., Ritchie, M., Francis, J., Cassisi, J., Morris, S., Townsend, M.H. Emotion recognition in schizophrenia: Further investigation of specific

- versus generalized performance deficit models. *Journal of Abnormal Psychology*, 2000, 109, 3, 512-516.
16. Townsend, M.H., Cambre, K.M., Barbee, J.G. Treatment of borderline personality disorder with mood instability with divalproex sodium: Series of 10 cases. *Journal of Clinical Psychopharmacology*, 2001,21, 249-251.
 17. Constans JI, Barbee, JG, Townsend, MH, Leffler H. Stability of worry-content in GAD patients: A descriptive study. *Journal of Anxiety Disorders*, 16(3):311-9, 2002
 18. Barbee, J.G., Billings, C.K., Bologna, N.B., Townsend, M.H. A follow-up study of DSM-III-R generalized anxiety disorder with syndromal and subsyndromal major depression. *Journal of Affective Disorders*, 73(3):229-36, 2003 Feb
 19. Townsend, M.H. Emergency Psychiatry Training for Third-Year Medical Students as Reported by U.S. Directors of Medical Student Education in Psychiatry. *Teaching and Learning in Medicine*, 16(3): 247-249, 2004.
 20. Townsend, M.H., Wilson M.S., Comorbid anxiety disorders and divalproex sodium use among partial hospital patients with psychotic disorders. *Comprehensive Psychiatry*, 46, 368-370, 2005
 21. Weisler, R.H., Barbee, J.G., Townsend, M.H. Mental health and recovery in the Gulf Coast after Hurricanes Katrina and Rita. *JAMA*, 296, 585-8, 2006.
 22. El-Mallakh, R.S., Weisler, R.H., Townsend, M.H., Ginsberg, L.D. Bipolar II disorder: current and future treatment options, *Annals of Clinical Psychiatry*, 18: 259-266, 2006.
 23. Townsend, M.H. Medical Student Education in Psychiatry One Year After Hurricane Katrina: Disaster and Renewal, *Academic Psychiatry*, 31:205-210, 2007.
 24. Townsend, M.H., Baier M.B., Becker J., Ritchie M.A., Blood Pressure, Heart Rate, and Anxiety in Schizophrenia, *Psychiatry Research*, 151:155-7, 2007
 25. Townsend M.H., Conrad E. J.: The therapeutic potential of escitalopram in the treatment of panic disorder, *Neuropsychiatric Disease and Treatment*, 3:835-838, 2007.
 26. Conrad E.J., Townsend M.H., Buccola N.B. Restoration of mental health services in New Orleans, *American Journal of Psychiatry*, 165:33, 2008
 27. Townsend M.H. The effect of Hurricane Katrina on medical student career choice, *Academic Psychiatry*, 36:258-259, 2012
 28. Thompson B.M., Haidet P, Borges N.J., Carchedi L.R., Roman B.J.B., Townsend, M.H., Butler A.P. Swanson D.P., Anderson M P., Levine R.E., Team Cohesiveness, Team Size, and Team Performance in Team-Based Learning Teams, *Academic Medicine*, 39:661-663.
 29. 29.Borges N.J., Thompson B.M., Roman B.J., Townsend M.H., Carchedi L.R., Cluver J.S., Frank J.B., Levine R.E. Team Emotional Intelligence, Team Interaction, and Gender During a Psychiatry Clerkship, *Academic Psychiatry*, in press.

Abstracts and/or Proceedings

1. Townsend, M.H., Mancusco, D.M., Mercante, D.E., Barbee, J.G. Generalized Anxiety Disorder: Long-term Outcome. American Psychiatric Association annual meeting, New Orleans, Louisiana, May, 1991.
2. Townsend, M.H., Mancusco, D.M., Mercante, D.E., Barbee, J.G. Generalized Anxiety Disorder: Long-term Outcome. American Psychiatric Association annual meeting, New Orleans, Louisiana, May, 1991.
3. Townsend, M.H., Wallick, M.M., Cambre, K.M. Gay and Lesbian Issues in Residency Training at U.S. Psychiatry Programs. American Psychiatric Association annual meeting, Washington, D.C., May, 1992.
4. Barbee, J.G., Townsend, M.H., Mercante, D.E. Monthly Follow-up Study of Patients with GAD. American Psychiatric Association annual meeting, San Francisco, California, May, 1993.
5. Townsend, M.H., Stock, M.R., Bland, I.J. Panic Disorder in a Homeless Population. American Psychiatric Association Annual Meeting, San Francisco, California, May, 1993.
6. Townsend, M.H., Barbee, J.G., Mercante, D.E. Personality, Anxiety and Worry in the Long-term Outcome of GAD. New Clinical Drug Evaluation Unit Annual Meeting, Boca Raton, Florida, June, 1993.
7. Stock, M.R., Townsend, M.H., Bland, I.J. HIV and Tuberculosis Among the Homeless Mentally Ill. American Psychiatric Association Annual Meeting, Philadelphia, Pennsylvania, May, 1994.
8. Townsend, M.H., Sullivan, L.S., Barbee, J.G. Pathological Anxiety, Personality, and Childhood Events. International Society for the Study of Behavioral Development, Amsterdam, The Netherlands, June, 1994.
9. Bologna N.B., Barbee J.G., Townsend M.H., Moersbacher J., Wright E. A Cognitive Psychophysical Measure of Divided Attention for Evaluation of CNS Effects of Psychoactive Drugs. New Clinical Drug Evaluation Unit Annual Meeting, Boca Raton, Florida, 1 May, 1996
10. Townsend M.H., Bologna N.B., Barbee J.G. Autonomic Dysfunction in Panic Disorder and Depression. American Psychiatric Association Annual Meeting, New York, New York, May, 1996.
11. Constans J.I., Barbee J.G., Townsend M.H. Stability of Worry/Content in GAD Patients. Anxiety Disorders Association of America Annual Meeting, New Orleans, Louisiana, March, 1997.
12. Barbee J.G., Billings C.K., Bologna N.B., Townsend M.H. A Follow-Up Study of DSM-III-R Generalized Anxiety Disorder with Syndromal and Subsyndromal Major Depression. American Psychiatric Association Annual Meeting, San Diego, California, May, 1997.
13. Townsend M.H., Weisbecker K., Barbee J.G., Winstead D.K. Compulsive Behavior in GAD and OCD. American Psychiatric Association annual meeting, San Diego, California, May, 1997

14. Francis J.L., Ritchie M., Combs D., Martin J., Penn D.L., Eckert S., Townsend M.H. The Effect of Context on Social Perception in Schizophrenia. Association for Advance of Behavioral Therapy Annual Convention, New Orleans, Louisiana, November 6, 1998.
15. Townsend M.H. "Two Schedules of Olanzapine in the Treatment of Agitation in Patients with Schizophrenia and Schizoaffective Disorder," New Clinical Drug Evaluation Unit annual meeting, Phoenix, Arizona, May 28, 2001
16. Townsend MH "Comorbid Anxiety and Treatment among Outpatients with Schizophrenia and Schizoaffective Disorder," New Clinical Drug Evaluation Unit annual meeting, Phoenix, Arizona, May 29, 2001
17. Townsend MH "Emergency psychiatry Training for Third-year Medical Students as Reported by Directors of Medical Student Education in Psychiatry," Association of Directors of Medical Student Education in Psychiatry, Key Biscayne, Florida, June, 2002
18. Townsend MH, "Blood Pressure, Heart Rate and Anxiety in Schizophrenia," American Psychiatric Association Annual Meeting, San Francisco, CA, May 2003
19. Townsend M.H., Baier MB, Becker J, "Anxiety and Pulse in Acute Mania," Anxiety and Pulse in Acute Mania. American Psychiatric Association Annual Meeting, Atlanta, Georgia, May, 2005.
20. Townsend MH "Choice of Psychiatry as a Career Following Catastrophic Natural Disaster," Annual Meeting of the Association of Directors of Medical Student Education in Psychiatry, Portsmouth, NH, June 2009
21. Townsend MH "Emergency medicine and psychiatry: a 10-year examination of medical student choice of residency training," Association for Academic Psychiatry Annual Meeting, Pasadena, California, September 2010
22. Townsend MH "The Effect of Gender and Group Size on Peer Assessment in Team-Based Learning," Annual Meeting of the Team-Based Learning Consortium, Las Vegas, Nevada March 2011
23. Levine RE, Carchedi L., Roman B, Townsend, M., Cluver J, Frank J "Team Cohesiveness and Performance in Team-Based Learning Teams vs Small Groups" Annual Meeting of the Association of Directors of Medical Student Education in Psychiatry, June 2014

Invited Speeches and Workshops (since 2000)

1. "Generalized Anxiety Disorder: Both Sides Now," Tulane University School of Medicine, October 2000
2. "Treating Bipolar Disorders in Routine Clinical Practice," symposium presentation, American Psychiatric Association annual meeting, New Orleans, Louisiana
3. "New Options in the Treatment of Schizophrenia," Ochsner Foundation Hospital, March 2003

4. "Substance Dependence in Bipolar Disorder and Schizophrenia: A Role for Atypical Antipsychotics?" Tulane University School of Medicine, August 2004
5. "Bipolar II Disorder: Recognition and Treatment," Oklahoma University School of Medicine, Tulsa Oklahoma, April 2004
6. "Managing Bipolar Disorder: Focus on Mania, Maintenance, and Safety," US Psychiatric Congress, New Orleans, Louisiana, November 2006
7. "Issues in Depression," symposium discussant, American Psychiatric Association annual meeting, New York, New York, May 2004
8. "Antipsychotics," LSUHSC New Orleans Family Medicine Update, New Orleans, Louisiana, April 2004
9. "Update on the Management of Depression: Focus on Bipolar Depression," LSUHSC New Orleans Family Medicine Update, New Orleans, LA, April 2005
10. "Disaster Interventions for Disadvantaged Communities," Institute for Psychiatric Services, New York, New York, October 2006
11. "Psychiatric Service Delivery in the Aftermath of Katrina," Institute for Psychiatric Services, New York, New York, October 2006.
12. "Innovative Outpatient Experiences for the Psychiatric Clerkship," Annual Meeting of the Association of Directors of Medical Student Education in Psychiatry, Park City, Utah, June 23, 2007.
13. "Update on Bipolar Disorder and Bipolar Depression: Avoiding Mood Switches," 16th Annual Practical Psychopharmacology Update, Las Vegas, NV March, 2007
14. "Depression Update: New Mechanisms and Strategies," 16th Annual Practical Psychopharmacology Update, Las Vegas, NV, March 2007
15. "Evaluating Anticonvulsants in the Treatment of Bipolar Disorder: A Clinical Update," US Psychiatric Congress, Orlando, Florida, October 2007
16. "Psychiatry Sequelae and Treatment Recommendations Regarding Survivors of Trauma Due to Perceived Ethnic or Sexual Minority Status," American Psychiatric Association Institute for Psychiatric Services, Chicago, IL, October 2008
17. "Relation Between Psychiatric Recruitment and Natural Disaster: The Katrina Experience," American Psychiatric Association Annual Meeting, Washington, DC, May 2008
18. "Second Generation Antipsychotics in Major Depression and Anxiety Disorders," LSUHSC New Orleans Family Medicine Update, New Orleans, LA April 2008
19. "Lessons Learned from Hurricane Katrina applied to Hurricane Gustav," Annual Meeting of the American Psychiatric Association, New Orleans, LA, May 2010
20. "Homeless after Katrina: Treatment Strategies for a New and Underserved Population," American Psychiatric Association Annual Meeting, San Francisco, CA, May 2009
21. "Hurricane Katrina and Hurricane Sandy: Disaster Psychiatry and Medical Education," invited address, New York Medical College, New York, NY, December 2012
22. "Using Team-Based Learning in the Psychiatry Clerkship," Association of Directors of Medical Student Education in Psychiatry Annual Meeting, Blaine, WA, June 2012

23. "Obsessive-Compulsive Disorder: Making the Most of the 20-Minute Med Check," Annual Meeting of the Mississippi Psychiatric Association, Point Clear, AL, February 2012
24. "A Comparison of Team Cohesiveness and Performance in Team-Based Learning Teams versus Conventional Student Groups," co-author, Southern Group on Educational Affairs Annual Meeting, Savannah, GA, April 2013

Industry-Sponsored, Unrestricted CME Lecture Series

1. "Understanding the Neurobiology of Major Depressive Disorder," Bristol-Myers Squibb, 2007
2. "Economic Burden of Bipolar Disorder: Balancing Health Related Quality of Life and Medical Cost Outcomes," Abbot Laboratories, 2005
3. "Identifying Bipolar Disorder: The Importance of Differentiating Bipolar Disorder from Unipolar Depression," Astra-Zeneca, 2005
4. "Identification and Management of Bipolar Disorder in the Primary Care Setting," Astra-Zeneca, 2005
5. "Achieving Successful Outcomes in the Management of Bipolar Disorder: The Efficacy and Safety of Available Therapies," Astra-Zeneca, 2004
6. "Management of Bipolar Disorder Mania with Antipsychotics and Their Outcome," Bristol-Myers Squibb, 2003
7. "Single-Isomer Drugs: Chemistry, Biology, and Drug Discovery," Forest Laboratories, 2002
8. "An Evidence-Based Approach to Selecting Antidepressant Therapy," Forest Laboratories, 2002
9. "Identifying and Treating Depression Complicated by Comorbid Conditions," Forest Laboratories, 2001
10. "Bipolar Disorder: Therapeutic Opportunities," Parke Davis, 2000
11. "Depression and Comorbid Conditions: A Psychiatric Perspective," Forest Laboratories, 2000

Grants and Contracts

Current Research

1. Hyperbaric Oxygen Treatment of Chronic Mild-Moderate Blast-Induced Traumatic Brain Injury (TBI) /Post-Concussion Syndrome (PCS). Department of Defense.
2. A 12-Month Randomized, Open-label Study of Caregiver, Psychoeducation and Skills Training in Patients with Recently Diagnosed with Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder and Receiving Paliperidone Palmitate or Oral Antipsychotic Treatment. Johnson and Johnson.

Completed Research

1. A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients with Bipolar I Disorder. Otsuka.
2. A Fifteen-Month, Prospective, Randomized, Active-Controlled, Open-Label, Flexible-Dose Study of Paliperidone Palmitate Compared with Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults with Schizophrenia Who Have Been Recently Released From Jail. Ortho-McNeil Janssen Scientific Affairs.
3. Relationship between Functioning of Teams in a Team Based Learning Curriculum and the Performance of Teams on a High Stakes NBME Examination Southern Group on Educational Affairs, AAMC
4. "A Randomized, Double-Blind, Active and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Extended-Release Paliperidone as Maintenance Treatment After an Acute Manic or Mixed Episode Associated Bipolar I Disorder. Johnson and Johnson.
5. "A 52-week, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of an intramuscular depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia." Otsuka.
6. A Twelve-week, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group, Active-controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of Bupropion Hydrochloride Extended-release (Wellbutrin XL) and Extended-release Venlafaxine (EffexorXR, 75-225 mg/day) in Subjects with Major Depressive Disorder. GlaxoSmithKline, (Completed 2005)
7. "An International, Multicenter, Large Simple Trial (LST) to Compare the Cardiovascular Safety of Ziprasidone and Olanzapine." (Completed 2006) Pfizer.
8. A Study of Olanzapine and Fluoxetine in Combination for Treatment Resistant Depression without Psychotic Features. Eli Lilly and Company (Protocol H6P-MC-HDAO). Sub-Investigator. (Completed 2006)
9. "A Multicenter, open-label, flexible-dose, parallel-group evaluation of the cataractogenic potential of quetiapine fumarate (SEROQUEL) and risperidone (RISPERDAL) in the long-term treatment of patients with schizophrenia or schizoaffective disorder." (Completed 2006)
10. "A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Paliperidone Palmitate in Subjects with Schizophrenia." Johnson & Johnson. (Completed 2005)
11. "A Randomized, Double-Blind, Placebo and Active Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of 2 Fixed Dosages of

- Extended Release Oros Paliperidone (6 and 12 mg/Day) and Olanzapine (10 mg/Day) with Open Label Extension in the Treatment of Subjects with Schizophrenia (RO76477-SCH-304) an Open-Label Extension to RO76477-SCH-304 STUDY (RO76477-SCH-704) (Completed 2005).
12. Randomized, Double-Blind, Placebo Controlled Study of Aripiprazole Monotherapy in the Treatment of Acutely Manic Patients With Bipolar I Disorder.” Bristol Meyers Squib. (Completed 2006)
 13. “A Phase III, Three-Week, Multicenter, Randomized Double-Blind Placebo-Controlled, Parallel Group Safety and Efficacy Study of Extended-Release Carbamazepine in the Treatment of Bipolar I Disorder.” Shire Pharmaceutical Development, Incorporated (Completed 2003).
 14. A Double-Blind Multicenter Placebo and Active-Controlled Acute and Extension Study of Two Doses of MK-0869 in the Treatment of Patients with Major Depressive Disorder. Merck Research Laboratories (Protocol 061-00) Sub-investigator.
 15. The Double-Blind Comparison of the Safety and Efficacy of Escitalopram and Fluoxetine in the Treatment of Fluoxetine Nonresponders. (Forest Laboratories, Incorporated (Protocol SCT-MD-21) Sub-investigator.
 16. An Open-Label Extension Study of the Safety and Efficacy of Lu26-054 in Patients with Major Depressive Disorder. Forest Laboratories, Incorporated (Protocol SCT-MD-19) Sub-investigator.
 17. An Evaluation of the Safety and Efficacy of Lu 26-254 in the Prevention of Depression Recurrence. Forest Laboratories, Incorporated (Protocol SCT-MD-11) Sub-investigator.
 18. “ A Prospective, Randomized, Double-Blind, Placebo- and Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Iloperidone (4, 8, and 12 mg/day) Given BID. PI for 42 days to Schizophrenic Patients with Acute or Subacute Exacerbations, Followed by a Double-Blind, Active-Controlled, Flexible-Dose, Long-Term, 20 Week Phase with Iloperidone (4, 8, 12 or 16 mg/day) Given QD.” Novartis Pharmaceuticals, Inc. “
 19. Fixed-dose vs. Dose-escalation Schedule for Oral Olanzapine in the Treatment of Schizophrenia, Schizoaffective Disorder and Mania with Psychotic Features Accompanied by Agitation.” Eli Lilly Pharmaceuticals. (Completed 2000)
 20. “A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Safety and Efficacy and Effects on Sexual Functioning of Wellbutrin (Bupropion HCl) Sustained Release (SR) and Fluoxetine in Outpatients with Moderate to Severe Recurrent Major Depression.” Glaxo-Wellcome, Incorporated. (Completed 2000)
 21. “A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Aripiprazole in the Maintenance Treatment of Patients with Bipolar Disorder.” Bristol-Myers Squibb and Otsuka American Pharmaceutical. (Completed 2000)
 22. “A Multicenter, Randomized, Double-Bind, Placebo Controlled Study of Two Fixed Doses of Aripiprazole in the Treatment of Hospitalized Patients with Acute Mania.” Bristol-Myers Squibb and Otsuka American Pharmaceutical. (Completed 2000)

23. "A Double-Blind, Three-Armed, Fixed-Dose, Placebo-Controlled Dose-Finding Study with Sublingual Org 5222 in Subjects with Acute Phase Schizophrenia." (Completed 2000) Organon, Incorporated. (Completed 2000)
24. "A Long-Term Maintenance of Subjects with Schizophrenia with Org 522." Organon, Incorporated. (Completed 2000)

Research Completed Prior to 2000

25. "A Double-Blind, Placebo-Controlled Parallel Group Assessment of the Safety and Efficacy of Two Doses of the Selegiline Transdermal System (10mg and 20mg) in Patients with Major Depression." Somerset Pharmaceuticals, Inc.
26. Reboxetine vs. Placebo in the Treatment of Major Depression Disorder Resistant to Fluoxetine." Pharmacia and Upjohn. Sub-Investigator.
27. "A Placebo-Controlled Study of Pregabalin in Patients with Acute Mania." Parke-Davis.
28. "A Sustained Efficacy Study of Pregabalin in Patients with Social Phobia." Parke-Davis.
29. "A Placebo-Controlled Study of Pregabalin and Paroxetine in Patients with Panic Disorder." Parke-Davis.
30. "An Open-Label Safety Study of Pregabalin in Patients with Anxiety Disorders." Parke-Davis.
31. "Flexible Dose Comparison of the Safety and Efficacy of S-Citalopram, Racemic Citalopram, and Placebo in the Treatment of Major Depressive Disorder." Forest Laboratories.
32. "A Double-Blind, Randomized, Multicenter, Parallel-Group Design Study to Evaluate the Efficacy and Safety of Two Dose Ranges of EMD 128 130 in Comparison with Placebo and Haloperidol in the Treatment of Schizophrenia." Merck Incorporated.
33. "An Open-Label Evaluation of the Efficacy, Safety and Dosing of Citalopram in Outpatients with Depression," Forest Pharmaceuticals.
34. "A Multicenter, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of LAMICTAL (Lamotrigine) Compared to Placebo and Lithium in the Treatment of an Acute Manic Episode in Patients with Bipolar Disorder: Incorporating Participation in Genotype Research Which is Optional for Both Study Centers and Patients." Glaxo Wellcome (Completed) PI.
35. "A Multicenter, Placebo, and Active Control, Double-Blind Randomized Study of the Efficacy, Safety and Pharmacokinetics of M100907 (10 and 20 mg/day) in Schizophrenic and Schizoaffective Patients," Hoechst Marion Roussel. (Completed) PI.
36. "A Multicenter, Double-Blind, Placebo Controlled Evaluation of the Safety and Efficacy of LAMICTAL (Lamotrigine) Compared to Placebo in the Treatment of an Acute Manic or Mixed Episode in Patients with Bipolar Disorder." Glaxo Wellcome, Incorporated. PI.

37. "A Double-Blind Trial of Three Fixed Doses of Nefazodone and Placebo in the Treatment of Patients with Panic Disorder." Bristol-Myers Squibb Company. Subinvestigator.
38. "A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Fixed-Dose Evaluation of the Safety and Efficacy of Lamotrigine in the Long-Term Prevention of Relapse and Recurrence of Depression and/or Mania in Patients with Bipolar I Disorder" Glaxo Wellcome.
39. "Fluoxetine vs. Placebo in Panic Disorder," Eli Lilly and Company.
40. "Divalproex Sodium in the Treatment of Patients with Borderline Personality Disorder and Prominent Mood Instability," Abbott Laboratories. Investigator-Initiated PI.
41. "A Multi-Center, Open, Randomized Comparison of ICI 294-636 (Seroquel) in Subjects with Schizophrenia and Schizoaffective Disorder." Zeneca Pharmaceuticals. PI.
42. "A Multi-Center, Open, Randomized Comparison of ICI 294-636 (Seroquel) in Subjects with Schizophrenia and Schizoaffective Disorder." Zeneca Pharmaceuticals. PI.
43. "The Evaluation of a Transdermal Buspirone Patch versus Placebo in Patients with Generalized Anxiety Disorder." SANO Corporation.
44. "Pramipexole in the Treatment of Patients with Severe Depression: A Pilot Trial." The Upjohn Company.
45. "A Double-Blind, Randomized Trial of Three Fixed Doses of Transdermal Buspirone Compared to Placebo in the Treatment of Anxious Outpatients," Bristol-Myers Squibb Company
46. "A Study of the Efficacy of Risperidone, Haloperidol and Clozapine in Treatment Resistant Schizophrenic Subjects." Janssen Research Foundation.
47. "Phase III, Six Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Three Fixed Doses of Oral Ziprasidone and Haloperidol in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder." Pfizer, Inc.
48. "Risperidone QD vs. BID Dosing in Schizophrenia." Janssen Pharmaceutica. PI
49. "A Phase II, Multicenter, Open Label Study Evaluating the Efficacy and Safety of Oral Ziprasidone (CP-88, 0591-1) in the Treatment of Subjects with Psychosis and Acute Agitation." Pfizer, Inc. PI.
50. "A One-Hundred and Fifty-Six Week (Three Year) Open Extension Study Evaluating the Safety and Outcome of 40-200 mg Daily of Oral Ziprasidone or 1-8 mg BID of Oral Risperidone Daily in the Treatment of Subjects Who Have Participated in Previous Ziprasidone Clinical Trials." Pfizer, Inc. PI.
51. "A Double-blind, Placebo-controlled Dose Escalation Study of the Safety and Efficacy of Oral Ondansetron in the Treatment of Patients with Panic Disorder." Glaxo, Inc.
52. "A Double-blind, Placebo-controlled Flexible Dose Response Study of BMS-118108 in Outpatients with Major Depressive Disorder." Bristol-Myers Squibb.
53. "Klonopin Dose Optimization Study." Roche Laboratories.

54. "Fixed-dose, Double-blind Study in Panic Disorder Comparing the Effects of Routine Clinical Taper and Taper by Progressive Placebo Substitution in Panic Patients Responding to Treatment with DeracynSR." The Upjohn Company.
55. "A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Two Doses of Ondansetron versus Placebo in the Treatment of Social Phobia."
56. "Zatoseptron in Patients with Generalized Anxiety Disorder." Lilly Research Laboratories.
57. "A Prospective, Randomized Double-blind, Placebo-controlled, Multicenter, Parallel-groups Comparison of the Efficacy and Safety of Abecarnil, Alprazolam, and Placebo in the Treatment of Generalized Anxiety Disorder." Sandoz Research Institute.
58. "Dose Response Study of Deracyn-SR Tablets in the Treatment of Generalized Anxiety Disorder and Associated Depressive Symptoms." The Upjohn Company.
59. "A Placebo-controlled, Double-blind, Parallel Trial of Fixed Doses of Brofaromine Hydrochloride in Patients with Social Phobia." Ciba-Geigy Corporation.
60. "A Nine-Week Open Label, Multicenter, Safety Trial of Flexible Dosage Ranges of Risperidone in the Treatment of Manic and Mixed Episodes Associated with Bipolar I Disorder." Janssen Research Foundation.
61. "The Efficacy and Safety of Flexible Dosage Ranges of Risperidone vs. Placebo in the Treatment of Manic Episodes Associated with Bipolar I Disorder." Janssen Research Foundation.